defects and chronic pain. He coined the term prolotherapy in his book Ligament and Tendon Relaxation:
Treated by Prolotherapy. 11 Akin to prolotherapy, PRP therapy seeks to initiate healing through the administration of a local irritating substance. 5 However, unlike prolotherapy, PRP therapy exploits the ability of platelets to directly deliver growth factors to sites of injury. 6 It is this property that allows PRP injections to both incite and augment inflammation and thus enhance tissue repair.
To our knowledge, the first evidence of the therapeutic effects of platelet-rich compounds was provided by the work of oral and plastic surgeons who reported enhanced bone healing after using PRP therapy to reduce blood loss. 12 As the understanding of platelets and their role in healing grew, physicians began to experiment with the role of platelets in wound healing.
Basic Science
Initially thought to be solely the bandages of the circulatory system, the contents of platelets, specifically α granules, have been found to contain a number of growth factors crucial to the reparative process ( Table 1 ). Cytokines that act as homing signals to circulating mesenchymal cells, mitogens that stimulate mitosis and proliferation of fibroblasts, and transcription factors that increase the production of collagen fibrils are all abundant within densely packed α granules in the cytoplasm of circulating platelets. 6 Histopathologic changes associated with chronic painful tendon injuries or tendonopathy exhibit degeneration and disorganization of collagen, hypercellularity, and little inflammation. 13 Gross changes resulting from the degenerative nature of the healing process include thickening, loss of mechanical properties such as resistance to overload stretching, and subjective pain. 14 A series of PRP injections was credited with accelerating the healing process and thus allowing the athlete to compete. 9 The efficacy of orthobiologics such as PRP to manage musculoskeletal ailments must be demonstrated and reproduced with positive outcomes from large clinical trials. In the current article, we provide a historical background and overview of the basic science of this new therapy and summarize the current state of research.
Historical Perspective
The idea of inducing inflammation to trigger the healing cascade has its roots in antiquity. Aulus Cornelius Celsus, a Roman encyclopedist, attempted to harness the healing properties of inflammation in helping to manage disease. 10 In the first century BCE, physicians treated patients with hydrocele (accumulation of fluid around the testes) by injecting saltpeter (potassium nitrate) in an attempt to induce scarring. 
Clinical Trials
We conducted a search on the US National Library of Table 2) . Herein, we describe some of the studies identified. The first studies were primarily pilot studies that sought to treat patients with chronically injured tendons, and many of these studies showed evidence of improved function. However, it was not until 2010 when the first widely recognized study, 17 consisting of an adequate control group and using randomization, was published in
JAMA. This randomized controlled study found no evidence of improvement in Achilles tendinopathy in the PRP therapy group vs the control group and was a major setback in gaining wider acceptance of this therapy. the corticosteroid group showed improvement that then declined, whereas the PRP group progressively improved.
18
A 2-year follow-up study 19 was conducted to analyze further long-term benefits of PRP therapy compared with corticosteroids. When results were compared with the 1-year follow-up, the corticosteroid group showed a decline, whereas the PRP group's benefit continued to be maintained. 19 The primary analysis consisted of VAS pain scores and DASH outcome scores. Baseline VAS and DASH scores were compared between groups.
Both groups demonstrated statistically significant improvement across time (intention-to-treat principle). However, the DASH scores of the corticosteroid group returned to baseline, and the PRP group maintained a statistically significant improvement (as-treated principle). Another study 21 showed positive results in patients with osteoarthritis of the knee. Thirty patients were ran- 
Current Issues
The lack of standardization of PRP preparations, the various matrices used to localize the injections at sites of injury, and the differing techniques of activation (ie, inducing the release of growth factors from the concen- tocols, and the high cost of preparing PRP samples, it is important that the efficacy and safety of PRP treatments be further evaluated.
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injection, remain a barrier to further acceptance and critical evaluations. Thrombin as an activator has been shown to release transforming growth factor β1 and plateletderived growth factor β1 immediately on induction and to promote gelation (clotting), thus preventing diffusion away from the target lesion. In contrast, soluble collagenactivated PRP clots, which promote gelation, tend to release more steady concentrations over a longer time, resulting in a net 80% greater cumulative release over 7 days. 28 Centrifugation methods have also shown varying levels of platelet-aggregating capacities. 
Conclusion
Greater understanding of the complex interplay between the immune system and signaling from wound tissue has led to increased use of PRP therapy in musculoskeletal injuries. The use of autologous blood as the source of hyperconcentrated platelets in PRP therapy circumnavigates any potential cross-reaction from infusions. Although PRP therapy is available throughout the United States and other countries, given questionable insurance reimbursements, lack of standardization of preparation and procedural pro-
